High Growth Tech Stocks In The United States To Watch

Over the last 7 days, the United States market has remained flat, yet it is up 21% over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and optimistic forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and solid financial health.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	29.07%	27.57%	★★★★★★
AsiaFIN Holdings	51.75%	82.69%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
AVITA Medical	27.78%	55.33%	★★★★★★
TG Therapeutics	29.48%	45.20%	★★★★★★
Bitdeer Technologies Group	51.86%	122.49%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.83%	59.08%	★★★★★★
Lumentum Holdings	21.25%	118.58%	★★★★★★
Travere Therapeutics	30.33%	61.73%	★★★★★★

Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Apellis Pharmaceuticals (NasdaqGS:APLS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases, with a market cap of approximately $3.53 billion.

Operations: Apellis focuses on developing and commercializing proprietary therapeutics, generating $715.22 million in revenue from these activities. The company's strategy centers on inhibiting the complement system to address autoimmune and inflammatory diseases.

Apellis Pharmaceuticals, a biotechnology firm focusing on rare diseases, recently announced significant regulatory progress in Europe and Australia that underscores its potential within the high-growth tech sector of biotech. The European Medicines Agency’s validation of Aspaveli® for rare kidney diseases and the Australian approval of SYFOVRE® for a severe eye condition highlight Apellis's innovative approach to unmet medical needs. These developments are pivotal as Apellis transitions from R&D to commercial stages, evidenced by a robust 61.32% forecasted annual earnings growth and an R&D investment trend that aligns with its strategic focus on novel therapies. This trajectory sets Apellis apart in a competitive industry where innovation directly correlates with market success.

• Dive into the specifics of Apellis Pharmaceuticals here with our thorough health report.

• Review our historical performance report to gain insights into Apellis Pharmaceuticals''s past performance.

Oracle (NYSE:ORCL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Oracle Corporation provides a range of products and services designed to meet the needs of enterprise information technology environments globally, with a market capitalization of $507.70 billion.

Operations: Oracle generates revenue primarily through its Cloud and License segment, which accounts for $46.68 billion, complemented by Services at $5.27 billion and Hardware at $2.98 billion. The company's business model focuses on enterprise IT solutions across these key segments, with a significant emphasis on cloud technology offerings.

Oracle's strategic advancements in AI, particularly within its Oracle Fusion Cloud Human Capital Management (HCM), underscore its commitment to enhancing workforce productivity and the employee experience. The introduction of role-based AI agents is set to transform HR operations by automating end-to-end workflows, thereby allowing employees to focus on higher-value tasks. This innovation not only boosts individual performance but also aligns with broader industry trends towards digital transformation and efficiency in human resources management. Oracle's recent debt financing activities, totaling over $7 billion across various maturities, reflect a robust financial strategy aimed at optimizing capital structure and funding ongoing innovation and potential acquisitions. These moves demonstrate Oracle's proactive approach in managing financial health while investing heavily in technology that keeps it competitive in a rapidly evolving tech landscape.

• Click to explore a detailed breakdown of our findings in Oracle's health report.

• Understand Oracle's track record by examining our Past report.

Tuya (NYSE:TUYA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tuya Inc. provides a specialized Internet of Things (IoT) cloud development platform, serving both the People’s Republic of China and international markets, with a market cap of approximately $1.81 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $280.97 million.

Tuya's recent strategic maneuvers, including a pivotal integration with Google Home APIs and a partnership with Chery, underscore its robust positioning in the smart home and automotive sectors. These collaborations enhance Tuya's ecosystem, making it more accessible and enhancing user experiences across platforms. Financially, Tuya is on an upward trajectory with revenue growth forecasted at 15.8% annually, outpacing the US market average of 8.9%. Moreover, earnings are expected to surge by 124.38% per year, reflecting strong business performance and market confidence in its innovative solutions. This financial vitality is complemented by Tuya’s commitment to R&D, ensuring sustained innovation and competitiveness in the high-growth tech landscape.

• Take a closer look at Tuya's potential here in our health report.

• Gain insights into Tuya's past trends and performance with our Past report.

Make It Happen

• Click this link to deep-dive into the 230 companies within our US High Growth Tech and AI Stocks screener.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com